CCL20 Locked Dimer Polypeptide for Psoriasis Treatment

The patent employs a small molecule compound as a cost-effective alternative to expensive monoclonal antibodies. Small molecules are generally cheaper to manufacture, have simpler production processes, and can be administered orally rather than requiring expensive injection infrastructure. This principle directly addresses the cost effectiveness problem while maintaining therapeutic effectiveness through targeted CCL20 inhibition.

The invention changes the molecular parameters by designing a small molecule compound with specific structural features that enable CCL20 binding. By altering the chemical structure parameters (molecular weight, functional groups, binding affinity), the patent achieves effective CCL20 inhibition at lower cost compared to large protein-based biologics.

The patent applies local quality by targeting CCL20 specifically in inflamed tissues rather than systemically affecting all T cell functions. The small molecule compound is designed to bind CCL20 at its site of action in inflammatory lesions, selectively blocking chemotaxis to affected areas while leaving normal T cell recruitment and immune surveillance functions intact. This localized approach reduces harmful inflammation without broadly suppressing T cell adaptability.

The small molecule compound acts as an intermediary that selectively blocks the CCL20-CCR6 interaction without directly affecting T cell receptors or other immune signaling pathways. By mediating the inhibition at the chemokine-receptor binding level rather than at the T cell functional level, the patent achieves inflammation reduction while preserving T cell versatility and normal immune responses.